Description
About
Manasamithram Gulika (also known as Manasamitra Vatakam) is a classical Ayurvedic formulation widely used for mental health and neurological well-being. It contains a blend of powerful herbs such as Brahmi, Vacha, Jatamansi, Shankhpushpi, and other Medhya Rasayanas (brain tonics). Traditionally, it is prescribed for improving memory, concentration, mood, and sleep quality.
It is considered one of Ayurveda’s best medicines for neuropsychiatric conditions, stress, and cognitive enhancement.
Uses
-
Improves memory, concentration, and learning ability
-
Reduces stress, anxiety, and depression
-
Supports in insomnia and disturbed sleep
-
Beneficial in epilepsy, seizures, and nervous system disorders
-
Supports therapy in mental health imbalances
-
Enhances mental clarity and emotional stability
Benefits
-
Medhya Rasayana: Promotes brain health and intelligence
-
Anxiolytic: Reduces stress and anxiety
-
Neuroprotective: Supports nervous system health
-
Mood stabilizer: Helpful in depression and emotional disturbances
-
Improves sleep: Natural aid for insomnia
-
Cognitive enhancer: Boosts memory and focus
Different Names in Different Languages
-
Sanskrit: Manasamitra Vatakam / Manasamithram Gulika
-
Tamil: மனசமித்ரம் குலிகை
-
Telugu: మనసమిత్రం గులికా
-
Malayalam: മനസമിത്രം ഗുളിക
-
Kannada: ಮನಸಮಿತ್ರಂ ಗುಳಿಕೆ
-
Hindi: मनसामित्रम् गोली
-
English: Manasamithram Gulika Tablets
Dosage & Administration
-
Adults: 1–2 tablets once or twice daily with milk or warm water
-
Children: ½ – 1 tablet (only under physician guidance)
-
Can be used as an adjuvant with other Ayurvedic or allopathic treatments
-
Should be taken under medical supervision, especially in psychiatric or neurological conditions
Precautions
-
Must be taken only under Ayurvedic physician guidance
-
Avoid self-medication, especially in cases of severe mental disorders
-
Pregnant and lactating women should use cautiously
-
Overdose may cause drowsiness or gastric upset
-
Store in a cool, dry place away from direct sunlight
Reviews
There are no reviews yet.